

PRESS RELEASE

Egetis Therapeutics AB
Stockholm, Sweden, May 5, 2022

Egetis initiates build-up of medical affairs and the commercial team with the appointment of three senior leaders

- Marianne Berrens-Peijnenburg joins as Global Head of Medical Affairs
- Nadia Georges joins as Global Head of Market Access & Pricing
- Peter Verwajen joins as Global Head of Marketing & Brand Strategy

Stockholm, Sweden, May 05, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced three key appointments to medical affairs and the commercial team to deliver on activities to ensure successful launches after anticipated approvals of *Emcitate* in USA and Europe in 2024. Marianne Berrens-Peijnenburg joins as Global Head of Medical Affairs, Nadia Georges joins as Global Head of Market Access & Pricing, and Peter Verwajen joins as Global Head of Marketing & Brand Strategy.

Nicklas Westerholm, CEO of Egetis, commented: *“Through the announced recruitments we bring additional industry leading rare disease expertise and experience in medical affairs and commercialization to the Company. The timing is right for Egetis to start stepwise building our international teams ahead of the expected *Emcitate* submissions for market approval in Europe and US next year to ensure a successful launch. We plan to commercialize *Emcitate* on our own in Europe and North America, with combined teams of around 50 FTEs at launch.”*

Henrik Krook, VP Commercial Operations of Egetis, continued: *“I am very pleased to welcome Marianne, Nadia and Peter to the Egetis team for the important work of ensuring successful preparations for the anticipated launch of *Emcitate*. There has been great interest among senior pharma leaders to join Egetis. Our selected leaders bring successful track records in orphan diseases with specific skills in areas such as enhancing disease awareness and demonstrating product value to secure funding/reimbursement of treatment.”*

Marianne Berrens-Peijnenburg is a Medical Doctor who, in the role as Global Head of Medical Affairs, will be responsible for establishing small medical affairs teams in North America and Europe to drive activities such as health care professional education on MCT8 deficiency and stimulating increased diagnosis of patients. She has previously had international and senior roles at companies such as Santhera, Sanofi Genzyme and J&J. Marianne will be based in The Netherlands.

Nadia Georges will, in the role as Global Head of Market Access & Pricing, lead the development of the *Emcitate* pricing strategy and ensure that national payers recognize the full value of *Emcitate* treatment and thereby support funding/reimbursement. She brings experience from global and international roles at companies such as Ferring, Takeda and Sanofi. Nadia will be based in Switzerland.

Peter Verwajen will, in the role as Global Head of Marketing & Brand Strategy, lead the development and execution of the *Emcitate* launch plan, including market preparations through executing initiatives such as disease awareness campaigns through the web, social media and at congresses for neurologists and endocrinologists. He has previously had international and senior positions at companies such as Santhera, Roche and Actelion. Peter will be based in The Netherlands.

EGETIS THERAPEUTICS

For further information, please contact:

Nicklas Westerholm, CEO
+46 (0) 733 542 062
nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations and Communications
+46 (0) 733 011 944
karl.hard@egetis.com